

Richard Melsheimer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6404701/publications.pdf>

Version: 2024-02-01

8
papers

267
citations

1478505

6
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

338
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. <i>American Heart Journal</i> , 2000, 140, 74-80.	2.7	83
2	<p>Remicade[®](infliximab): 20 years of contributions to science and medicine</p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 139-178.	3.2	78
3	Ca 72-4 radioimmunoassay for the detection of the tag-72 carcinoma-associated antigen in serum of patients. <i>Journal of Clinical Laboratory Analysis</i> , 1989, 3, 360-369.	2.1	64
4	The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. <i>Advances in Therapy</i> , 2021, 38, 2077-2093.	2.9	16
5	Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1257-1264.	1.3	12
6	Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 1-15.	3.2	8
7	Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade®. <i>BioDrugs</i> , 2018, 32, 405-414.	4.6	4
8	Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. <i>Current Medical Research and Opinion</i> , 2022, 38, 613-627.	1.9	2